Our Commitment to Safety Communication

The Prescribing Information is the primary source of information on the known and potential risks of ocrelizumab for relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

As of March 2022, more than 250,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 535,000 patient-years.¹

• >9500 patients in clinical trials and open-label extension
• >250,000 patients with post-marketing experience

The following ocrelizumab global safety updates are available. Click below to learn more:

Indication:

Ocrelizumab is indicated for the treatment of: 

• Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
• Primary progressive MS, in adults
  

Report an Adverse Event:
Phone: (888) 835-2555
Hours: 24 hrs/day, 7 days/week

Medical Communications:
Submit a question online
Phone: (800) 821-8590
Hours: Monday - Friday, 5am - 5pm PT

Contact an MSL:
Request follow-up with a Genentech medical science liaison (MSL)